EC Grants Marketing Authorization for Subcutaneous Formulation of Daratumumab
June 5th 2020The European Commission has granted marketing authorization to the Janssen Pharmaceutical Companies of Johnson & Johnson for Darzalex (daratumumab) subcutaneous formulation to treat adults with multiple myeloma.
TAE Life Sciences to Launch Drug Delivery Program After $30-Million Investment
June 4th 2020The investment will give the company the opportunity to accelerate the development of proprietary boron-10 target drugs while it develops its neutron beam accelerator technology for Boron Neutron Capture Therapy.